Now Seven Plants in China
DUSSELDORF, Germany, May 29 /CNW/ - The Gerresheimer Group today opened a
new plant for pharmaceutical glass packaging in China. The high-tech
production facility constructed in Danyang (Jiangsu Province) covers 16,000
square meters. Specializing in high-quality pharmaceutical vials and
cartridges for injection systems it serves the pharma & life science industry
on both a local and international level. Dr. Axel Herberg, CEO of Gerresheimer
AG, describes the investment as a very important strategic step for further
business expansion in Asia. In China, Gerresheimer now operates seven
production plants for highly specific glass and plastic products.
The new facility belongs to Gerresheimer Shuangfeng, a Chinese subsidiary
of the Group, which was acquired in 2006 and now already has production plants
in three locations with a total of more than 150 production lines. With
investment in future-oriented technologies and a high-quality range of vials,
ampoules and cartridges, it has in just a few years developed into the market
leader in China, said Dr. Max Raster, member of the Management Board of
Gerresheimer AG with responsibility for the Tubular Glass Division, at the
opening ceremony on May 29, 2009.
"'Top quality produced in China' is the corporate philosophy here which
binds us directly to the ambitious objectives for development of the local
economy and the Jiangsu region," Raster said. At the gala opening he joined
Chao Xingsong, the Managing Director of Gerresheimer Danyang, in welcoming
representatives from the world of politics and the administration as well as a
large number of national and international customers who clearly showed they
were impressed by the high technical standard.
The state-of-the-art plant in the up-and-coming city with 800,000
inhabitants just 250 kilometers to the west of Shanghai is of outstanding
strategic importance for the globally active Gerresheimer Group. A key area of
focus for it is the rapidly growing Asian pharma market with its constantly
rising quality demands in terms of packaging and drug delivery. In the
unanimous assessment of experts, China is already the fifth largest pharma
market in the world.
In parallel with its local status as a technology advanced pharma glass
plant the Danyang facility offers ideal conditions and flexible expansion
possibilities to enable it to supply customers with high-quality specialist
products in neighboring Asian countries and other market regions as well. "We
work at the highest level of internationally recognized quality standards,"
Raster stresses. The technical production processes are for example monitored
by in-line camera systems - a product control process which is by no means
universal industry practice in China or elsewhere. The clean-room concept also
reflects the latest development status.
In Danyang, which has for years been regarded as a highly attractive
industrial location for foreign investors in particular, Gerresheimer
Shuangfeng also has a second production plant exclusively for pharmaceutical
vials. In addition, the company manufactures vials and ampoules in Zhenjiang,
also in the Province of Jiangsu. Four other plants of the Gerresheimer Group
also manufacture in the country. In total, Gerresheimer employs around 1,500
people in China.
Gerresheimer employs around 10,000 people in 42 locations in Europe,
America and Asia. In the financial year 2008, worldwide sales totalled
EUR1.06bn. The product portfolio ranges from pharmaceutical vials made of
glass and plastic through to complex drug-delivery systems for the pharma &
life science industry. These include sterile syringes, inhalers and other
system-based approaches for safe dosage and application of medications. The
Group enjoys a leading position in markets which are characterised by high
technical and regulatory barriers.
For further information:
For further information: Contact Press, Burkhard Lingenberg, Director
Corporate Communication & Marketing, Phone +49-211-6181-250, Fax
+49-211-6181-241, e-mail firstname.lastname@example.org; Contact Investor
Relations, Anke Linnartz, Director Corporate Investor Relations, Phone
+49-211-6181-314, Fax +49-211-6181-121, e-mail email@example.com